RT-qPCR (real-time quantitative polymerase chain reaction) method for detecting novel coronavirus Armike BA.2.1. 1 variant

By designing a specific primer and probe-based RT-qPCR method and combining it with the TaqMan probe method, the problems of rapid, accurate, and low-cost detection of the novel coronavirus BA.2.12.1 variant strain were solved, achieving high-throughput and low-cost detection of viral variant strains.

CN118996001AInactive Publication Date: 2024-11-22INST OF BIOLOGICAL & MEDICAL ENG GUANGDONG ACAD OF SCI
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411163314.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Currently, there is a lack of rapid, accurate, and low-cost detection methods for the novel coronavirus BA.2.12.1 variant. Existing technologies rely on expensive sequencing instruments and are complex to operate, making it difficult to achieve high-throughput detection.

Method used

The RT-qPCR method, which uses specific primers and probes and is combined with the TaqMan probe method, is simplified to two steps: nucleic acid extraction and RT-qPCR amplification, and detection is performed using a conventional real-time PCR instrument.

Benefits of technology

It enables rapid, sensitive, and highly specific detection of viral variants, reduces detection costs, decreases reliance on expensive instruments, increases detection throughput and accuracy, and reduces the risk of operational contamination.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention belongs to the technical field of biology, discloses an RT-qPCR (real-time quantitative polymerase chain reaction) method for detecting a novel coronavirus Armike BA.2.1. 1 variant, and particularly discloses a reagent which comprises a primer and a probe. The reagent provided by the invention can be used for detecting the novel coronavirus, can rapidly detect and identify the novel coronavirus, has extremely high detection sensitivity and specificity, and is accurate and reliable in detection result.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology, and specifically relates to an RT-qPCR method for detecting the novel coronavirus Omicron BA.2.12.1 mutant strain. Background Art

[0002] The novel coronavirus has multiple variants, among which the Omicron variant has infectivity and vaccine escape mutations. Currently, the BA.2 lineage has 57 mutations, 31 of which are in the S protein. The receptor binding domain (RBD) of the S protein is responsible for binding to the host receptor angiotensin-converting enzyme 2 (ACE2) and has the potential to increase infectivity and mediate the escape of vaccine-induced neutralizing antibodies. Therefore, mutations located in the RBD of the S protein have attracted great research attention.

[0003] The new coronavirus BA.2.12.1 is the next generation of the Omicron BA.2 variant. The transmission ability of BA.2 is at least 30% higher than that of BA.1. The transmission ability of BA.2.12.1 is estimated to be 23% to 27% higher than its predecessor BA.2. With its strong infectivity and rapid and hidden transmission, this strain has undergone important mutations at the T19I, L452Q, and S704L sites of the viral S protein.

[0004] Omicron is considered to be the most contagious new coronavirus variant so far, and BA.2.12.1 is the fastest-spreading of many Omicron variants. Therefore, a rapid detection method for the BA.2.12.1 variant of the new coronavirus is urgently needed.

[0005] Nucleic acid detection technology is a nucleic acid hybridization technology based on the principle of complementary pairing of double-stranded nucleic acids. Technicians synthesize a single-stranded nucleic acid sequence that is complementary to the DNA or RNA of a specific pathogen as a probe, and label it with biotin, radioactive isotopes, enzymes, etc., so that it can hybridize with the nucleic acid of the pathogen to be detected. The application of PCR technology allows the number of nucleic acids of pathogens to be detected to be amplified by tens of thousands, greatly improving the applicability and accuracy of nucleic acid detection technology. Summary of the invention

[0006] The first aspect of the present invention aims to provide a reagent.

[0007] The second aspect of the present invention aims to provide a kit.

[0008] The purpose of the third aspect of the present invention is to provide the use of the reagent of the first aspect of the present invention or the kit of the second aspect of the present invention.

[0009] The purpose of the fourth aspect of the present invention is to provide an RT-qPCR detection method for detecting the new coronavirus.

[0010] In order to achieve the above object, the technical solution adopted by the present invention is:

[0011] The first aspect of the present invention provides a reagent comprising a primer and a probe, wherein the nucleotide sequences of the primer and the probe are as follows:

[0012] ORF1ab-F: 5'-ATACTGAGTCCTCTTTATGCATTTGC-3',

[0013] ORF1ab-R: 5'-GTGCGGGAGAAAATTGATCGTA-3',

[0014] ORF1ab-P: 5'-CAGAGGCTGCTCGTGTT-3'; and / or

[0015] S-T19I-F: 5'-CATTCAACTCAGGATTTGTTCTTACC-3',

[0016] S-T19I-R: 5'-TGGTCCCAGAGACATGTATAGCA-3',

[0017] S-T19I-P: 5'-TGTTACTTGGTTCCATGCTA-3'; and / or

[0018] S-L452Q-F: 5'-AGCTTGATTCTAAGGTTGGTGGTAA-3',

[0019] S-L452Q-R: 5'-GGAAACCATATGATCGTAAAGGAAA-3',

[0020] S-L452Q-P: 5'-ACCAGTATAGATTGTTTAGGAAGTC-3'; and / or

[0021] S-S704L-F: 5'-CTAAGTCTCATCGGCGGGCA-3',

[0022] S-S704L-R: 5'-TGATGTCTTGGTCATAGACACTGG-3',

[0023] S-S704L-P: 5'-TGTAGCTAGTCAATCCATCA-3'.

[0024] In some embodiments of the present invention, both ends of the sequence of the probe are labeled with a fluorescent group and a quenching group, respectively.

[0025] In some embodiments of the present invention, the fluorescent group is at least one of FAM, Hex, VIC, TAMRA, ROX, Texas-Red and CY5.

[0026] In some embodiments of the present invention, the quenching group is at least one of TAMRA, MGB, BHQ1, BHQ2 and BHQ3.

[0027] In some embodiments of the present invention, the fluorescent group is connected to the 5' end of the probe.

[0028] In some embodiments of the present invention, the quencher group is connected to the 3' end of the probe.

[0029] In some preferred embodiments of the present invention, the 5' end of the ORF1ab-P is connected to the fluorescent group FAM, and the 3' end is connected to the quenching group BHQ1.

[0030] In some preferred embodiments of the present invention, the 5' end of the S-T19I-P is connected to the fluorescent group Texas Red, and the 3' end is connected to the quenching group BHQ2.

[0031] In some preferred embodiments of the present invention, the 5' end of the S-L452Q-P is connected to the fluorescent group HEX, and the 3' end is connected to the quenching group BHQ1.

[0032] In some preferred embodiments of the present invention, the 5' end of the S-S704L-P is connected to the fluorescent group VIC, and the 3' end is connected to the quenching group BHQ1.

[0033] The second aspect of the present invention provides a kit comprising the reagent of the first aspect of the present invention.

[0034] In some embodiments of the present invention, the kit further comprises a PCR reaction solution and a positive standard.

[0035] In some embodiments of the present invention, the PCR reaction solution includes a plasmid template, primers, a probe, and 2×Taq ProHS Universal U+Probe Master Mix (including DNA polymerase, dNTPs, buffer, and magnesium ions).

[0036] In some embodiments of the present invention, the positive standard is novel coronavirus pseudovirus RNA.

[0037] The third aspect of the present invention provides the use of the reagent of the first aspect of the present invention or the kit of the second aspect of the present invention in any one of (1) to (6):

[0038] (1) Identification of novel coronavirus;

[0039] (2) Preparing products for detecting or assisting in the detection of novel coronavirus;

[0040] (3) Detect whether the sample to be tested is a new coronavirus;

[0041] (4) Preparing products for detecting or assisting in detecting whether a sample to be tested is a novel coronavirus;

[0042] (5) Detect whether the sample to be tested is infected with the new coronavirus;

[0043] (6) Prepare products for detecting or assisting in detecting whether a sample is infected with the novel coronavirus;

[0044] The above applications are for non-disease diagnosis and treatment.

[0045] In some embodiments of the present invention, the new coronavirus is the new coronavirus Omicron BA.2.12.1 variant.

[0046] The fourth aspect of the present invention provides an RT-qPCR detection method for detecting the new coronavirus, comprising the step of using the reagent of the first aspect of the present invention and / or the kit of the second aspect of the present invention for detection, and the method is used for non-disease diagnosis and treatment.

[0047] In some embodiments of the present invention, the detection method comprises the following steps:

[0048] 1) Extracting nucleic acid from the sample to be tested;

[0049] 2) using the nucleic acid in step 1) as a template, performing RT-qPCR amplification reaction using the reagent or the kit, and collecting fluorescent signals;

[0050] 3) Determine whether the sample to be tested contains or is a new coronavirus based on the fluorescent signal.

[0051] The present invention adopts an improved PCR method for variant strain identification by detecting multiple mutation sites, and replaces the tedious operation steps of RT-PCR amplification-PCR product purification-on-machine testing of gene sequencing by RT-qPCR, shortening the time of detection and identification, and can be applied to the fluorescent quantitative PCR instrument equipped by most detection units to complete the accurate identification of virus variants, overcome the dependence on expensive sequencers, reduce the cost of testing, and increase the universality of the new coronavirus variant detection method. Through the 96-well RT-qPCR reaction plate, and with the help of the high sensitivity and low cost of TaqMan probe method qPCR, high-sensitivity, high-throughput, and low-cost detection of new coronavirus variants is achieved.

[0052] In some embodiments of the present invention, the RT-qPCR amplification reaction system in step 2) is: 10-15 μL of PCR reaction solution, a final probe concentration of 200-600 nM, a final upstream / downstream primer concentration of 200-700 nM, 1-3 μL of nucleic acid, and enzyme-free water added to 20 μL.

[0053] In some embodiments of the present invention, the RT-qPCR amplification reaction system in step 2) is: 10-15 μL of PCR reaction solution, a final probe concentration of 250-500 nM, a final upstream / downstream primer concentration of 400-500 nM, 1-3 μL of nucleic acid, and enzyme-free water added to 20 μL.

[0054] In some embodiments of the present invention, the RT-qPCR amplification reaction system in step 2) is: 10-15 μL of PCR reaction solution, a final probe concentration of 500-600 nM, a final upstream / downstream primer concentration of 450-500 nM, 1-3 μL of nucleic acid, and enzyme-free water added to 20 μL.

[0055] In some embodiments of the present invention, the RT-qPCR amplification reaction program in step 2) is: 40-55°C, 4-6 min; 94-96°C, 20-40 s; 94-96°C, 2-10 s, 55-65°C, 15-30 s, 35-45 cycles.

[0056] In some embodiments of the present invention, the RT-qPCR amplification reaction program in step 2) is: 50-55°C, 5-6 min; 94-96°C, 30-40 s; 95-96°C, 5-10 s, 60-65°C, 20-30 s, 35-40 cycles.

[0057] In some embodiments of the present invention, the result determination method of the detection method is: on the basis of the establishment of the experiment (that is, the negative control has no Ct value and no regular amplification curve, and the Ct value of the positive control should be less than 35), if the CT of the FAM, VIC, HEX, and Texas Red channels is ≥35, it is determined that there is no new coronavirus infection; the FAM channel CT is ≤35, the VIC, HEX, and Texas Red channels CT is ≥35, it is determined to be positive for the 2019-nCOV original strain; the FAM, VIC, HEX, and Texas Red channels CT is ≤35, it is determined to be the BA.2.12.1 mutant strain; the FAM, VIC, HEX, and Texas Red channels are for other cases, the results are invalid, and it is recommended to review.

[0058] In some embodiments of the present invention, the new coronavirus is the new coronavirus Omicron BA.2.12.1 variant.

[0059] The beneficial effects of the present invention are:

[0060] The reagent provided by the present invention can be used to detect the new coronavirus, can quickly detect and identify the new coronavirus, and has extremely high detection sensitivity and specificity, and the detection results are accurate and reliable.

[0061] The RT-qPCR detection method provided by the present invention has the following advantages:

[0062] Improve detection speed and reduce dependence on expensive instruments. The application speed of this patented technology in the identification of novel coronavirus mutants has been shortened from 6 to 8 hours to 1 hour. Moreover, this technical method does not rely on expensive sequencers, but only requires ordinary fluorescent optical quantitative PCR instruments to complete, reducing dependence on expensive instruments such as sequencers, saving sample transfer time, and minimizing uncontrollable factors.

[0063] Improve detection sensitivity. Based on the TaqMan probe method, RT-qPCR can detect viral nucleic acid mutations with a detection sensitivity of up to 1 copy / μL. The RT-qPCR amplification signal can detect viral nucleic acid mutations and avoid the influence of weak amplification signals on nucleic acid mutation detection based on gene sequencing.

[0064] Reduce detection costs and increase detection throughput. The entire experimental process of this technology only includes two steps: extraction of viral nucleic acid and QRT PCR. There are fewer experimental steps, and the required materials and labor costs are greatly reduced. It can be easily achieved through 96 or 384-well reaction plates to achieve high throughput of samples.

[0065] Low contamination rate and easy to operate. The current sequencing technology for detecting viral mutations requires steps such as viral RNA extraction, RT-PCR amplification, PCR product purification, and machine sequencing. Batch operations are prone to introduce operational contamination. This method only requires two steps: viral RNA extraction and RT-qPCR. The number of steps is reduced, and the corresponding operational contamination is also reduced. It is easy to detect a large number of samples at one time.

[0066] When used alone or in combination with other primer probes, the performance of the primer probe at each identification site is different: when used alone, it is not affected by other primers. When combined with other primers, it is easily affected by them and needs to be mutually identified. The primer probe dosage, reaction conditions, positive result judgment threshold and other sites have been optimized. BRIEF DESCRIPTION OF THE DRAWINGS

[0067] Figure 1 This is the standard curve of the detection method of the present invention (4 detection sites).

[0068] Figure 2 This is the gradient fluorescence amplification curve of ORF gene fragment ORF site.

[0069] Figure 3This is the gradient fluorescence amplification curve of the L452Q site of the S gene segment.

[0070] Figure 4 This is the gradient fluorescence amplification curve of the S704L site of the S gene segment.

[0071] Figure 5 This is the gradient fluorescence amplification curve of the T19I site of the S gene fragment.

[0072] Figure 6 It is the specific test result of the detection method of the present invention. DETAILED DESCRIPTION

[0073] The present invention is further described in detail below through specific examples.

[0074] It should be understood that these embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention.

[0075] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0076] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0077] Example 1 Design of primers and probes

[0078] The whole genome sequences of the novel coronavirus and the BA.2.12.1 mutant were analyzed and compared to identify the conserved regions of the whole genome. Following the design principles of primers and probes, specific probes and primers were designed in the conserved regions of the original novel coronavirus strain and each variant in ORF1ab, and specific primers and probe sequences were designed for the S gene mutations (21779ACT->ATT, T19I; 22975CTG->CAG, L452Q; 23731TCA->TTA, S704L). The primer and probe sequences are shown in Table 1.

[0079] Table 1 Primer and probe sequences

[0080]

[0081]

[0082] The above primers and probes were synthesized by Sangon Biotechnology (Shanghai) Co., Ltd.

[0083] The 5' end of ORF1ab-P is labeled with FAM fluorescent group, and the 3' end is labeled with quencher group BHQ1.

[0084] The 5' end of S-T19I-P is labeled with the Texas Red fluorescent group, and the 3' end is labeled with the quencher group BHQ2.

[0085] The 5' end of S-L452Q-P is labeled with a HEX fluorescent group, and the 3' end is labeled with a quencher group BHQ1.

[0086] The 5' end of S-S704L-P is labeled with VIC fluorescent group, and the 3' end is labeled with quencher group BHQ1.

[0087] Example 2 Preparation of standard positive template

[0088] The NCBI database was used to retrieve the gene sequence of SARS-CoV-2, and a BLAST comparative analysis was performed. Finally, high-quality gene sequences with a similarity of more than 95% with the gene sequences of each typical strain were selected, and Shanghai Bioengineering Co., Ltd. was commissioned to synthesize standard recombinant plasmids for each pathogenic microorganism.

[0089] Example 3 Establishment of detection method

[0090] An RT-qPCR method for identifying a novel coronavirus Omicron BA.2.12.1 variant, comprising the following steps:

[0091] (1) obtaining nucleic acid from a sample to be tested;

[0092] (2) Using the nucleic acid in step (1) as a template, perform RT-qPCR using the primers and probes designed and screened in Example 1. The 20 μL qPCR amplification reaction system is: 2×Taq Pro HS Universal U+Probe MasterMix 10 μL, 1 μL each of upstream / downstream primers (10 μM), 1 μL of TaqMan probe (10 μM), 2 μL of nucleic acid, and add sterile RNase-free water to 20 μL. The amplification reaction conditions are: 50°C, 5 min; 95°C, 30 s; 95°C, 5 s, 60°C, 20 s, 40 cycles;

[0093] (3) Amplification was performed using the above reaction conditions and system to obtain an amplification kinetic curve. The common logarithm (1gC) of the initial copy number of the standard (prepared in Example 2) was used as the abscissa, and the cycle threshold value (Ct value) was used as the ordinate to derive a standard linear regression equation (standard curve) to obtain its sensitivity test data.

[0094] (4) Result determination:

[0095] FAM, VIC, HEX, and Texas Red channel CT ≥ 35, determined to be free of novel coronavirus infection;

[0096] If the CT of FAM channel is ≤35 and the CT of VIC, HEX, and Texas Red channels is ≥35, it is determined to be positive for the original strain of 2019-nCOV;

[0097] FAM, VIC, HEX, and Texas Red channel CT≤35, determined to be a BA.2.12.1 variant strain;

[0098] For the rest of the FAM, VIC, HEX, and Texas Red channels, the results are invalid and a re-examination is recommended.

[0099] Example 4 Establishment of standard curve

[0100] The standard positive template (Example 2) was used as the template and diluted 10 times in a gradient to: 1×10 5 ~1×10 0 copies / μL, and then packaged and stored at -20°C; the diluted template was amplified using the reaction system and reaction procedure of Example 3 to obtain the template copy number and cycle number (Ct value). After the detection, the concentration lg value (X-axis) of each standard was plotted against its corresponding Ct value (Y-axis) to draw a standard curve.

[0101] Test results such as Figure 1 .

[0102] Example 5 Sensitivity Test

[0103] Use 1×10 5 ~1×10 0 The sensitivity test was carried out using a standard positive template with 3 copies / μL (Example 2), and 3 replicates were set for each gradient. The minimum detection concentration of the detection method of Example 3 was determined by observing the standard curve, and a standard curve was established with Ct value as the ordinate and copy number as the ordinate to evaluate its linear relationship and the sensitivity of the detection method.

[0104] The results are as follows Figure 2 to Figure 5 As shown in Table 2, when the site to be detected is ORF, the detection sensitivity is 4.24 copies / μL; when the variant site to be identified is T19I, the detection sensitivity is 4.92 copies / μL; when the variant site to be detected is L452Q, the detection sensitivity is 4.38 copies / μL; when the variant site to be detected is S704L, the detection sensitivity is 4.75 copies / μL.

[0105] Table 2 Positive detection rates of the four detection sites

[0106]

[0107]

[0108] Example 6 Specificity Test

[0109] The concentration used is 10 2 The recombinant plasmid with 100 copies / μL was used as the positive template, and the recombinant plasmids of influenza virus and purified water ddH2O were used as negative controls for respiratory diseases.

[0110] The test results showed that the novel coronavirus Omicron BA.2.12.1 variant tested positive in the specific test for respiratory disease-related pathogens, with no cross-reaction, and was negative with other respiratory pathogens, influenza B virus, with no cross-reaction ( Figure 6 ).

[0111] Through specific tests of respective pathogenic microorganisms, we verified the specificity of the TaqMan RT-qPCR method and proved that the established TaqMan RT-qPCR detection methods all have good specificity and can provide reliable technical support for the accurate diagnosis of related diseases.

[0112] The embodiments of the present invention are described in detail above in conjunction with the accompanying drawings, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.

Claims

1. A reagent comprising a primer and a probe, wherein the nucleotide sequences of the primer and the probe are as follows: ORF1ab-F: 5'-ATACTGAGTCCTCTTTATGCATTTGC-3', ORF1ab-R: 5'-GTGCGGGAGAAAATTGATCGTA-3', ORF1ab-P: 5'-CAGAGGCTGCTCGTGTT-3'; and / or S-T19I-F: 5'-CATTCAACTCAGGATTTGTTCTTACC-3', S-T19I-R: 5'-TGGTCCCAGAGACATGTATAGCA-3', S-T19I-P: 5'-TGTTACTTGGTTCCATGCTA-3'; and / or S-L452Q-F: 5'-AGCTTGATTCTAAGGTTGGTGGTAA-3', S-L452Q-R: 5'-GGAAACCATATGATCGTAAAGGAAA-3', S-L452Q-P: 5'-ACCAGTATAGATTGTTTAGGAAGTC-3'; and / or S-S704L-F: 5'-CTAAGTCTCATCGGCGGGCA-3', S-S704L-R: 5'-TGATGTCTTGGTCATAGACACTGG-3', S-S704L-P: 5'-TGTAGCTAGTCAATCCATCA-3'.

2. The reagent according to claim 1, characterized in that Both ends of the probe sequence are labeled with a fluorescent group and a quenching group respectively.

3. The reagent according to claim 2, characterized in that The fluorescent group is at least one of FAM, Hex, VIC, TAMRA, ROX, Texas-Red and CY5; and / or the quenching group is at least one of TAMRA, MGB, BHQ1, BHQ2 and BHQ3.

4. A kit, characterized in that: The kit comprises the reagent according to any one of claims 1 to 3.

5. The kit according to claim 4, characterized in that The kit also includes a PCR reaction solution and a positive standard.

6. Use of the reagent according to any one of claims 1 to 3 or the kit according to claim 4 or 5 in any one of (1) to (6): (1) Identification of novel coronavirus; (2) Preparation of products for detecting or assisting in the detection of novel coronavirus; (3) Detect whether the sample to be tested is a new coronavirus; (4) Preparing products for detecting or assisting in detecting whether a sample to be tested is a novel coronavirus; (5) Detect whether the sample to be tested is infected with the new coronavirus; (6) Preparing products for detecting or assisting in detecting whether a sample is infected with the novel coronavirus; The above applications are used for diagnosis and treatment of non-diseases; Preferably, the novel coronavirus is the novel coronavirus Omicron BA.2.12.1 variant.

7. A RT-qPCR detection method for detecting the novel coronavirus, comprising the step of using the reagent described in any one of claims 1 to 3 and / or the kit described in claim 4 or 5 for detection, wherein the method is used for non-disease diagnosis and treatment.

8. The detection method according to claim 7, characterized in that: The detection method comprises the following steps: 1) Extracting nucleic acid from the sample to be tested; 2) using the nucleic acid in step 1) as a template, performing RT-qPCR amplification reaction using the reagent or the kit, and collecting fluorescent signals; 3) Determine whether the sample to be tested contains or is a new coronavirus based on the fluorescent signal; Preferably, the novel coronavirus is the novel coronavirus Omicron BA.2.12.1 variant.

9. The detection method according to claim 8, characterized in that: The RT-qPCR amplification reaction system in step 2) is: 10-15 μL of PCR reaction solution, a final probe concentration of 200-600 nM, a final upstream / downstream primer concentration of 200-700 nM, 1-3 μL of nucleic acid, and enzyme-free water added to 20 μL.

10. The detection method according to claim 9, characterized in that: The RT-qPCR amplification reaction program in step 2) is: 40-55°C, 4-6 min; 94-96°C, 20-40 s; 94-96°C, 2-10 s, 55-65°C, 15-30 s, 35-45 cycles.

Citation Information

Patent Citations

  • Kit for detecting novel coronavirus and Omicron variant typing and application thereof

    CN116445659A

  • Primer, probe and controls for detection and discrimination of covid-19 and other coronaviruses diagnostic assay for the human virus causing covid-19-COV-2(covid-19) and its variants

    WO2023076639A1